Microalbuminuria and left ventricular hypertrophy among newly diagnosed black African hypertensive patients: a cross sectional study from a tertiary hospital in Uganda

BMC Research Notes

Robert Kalyesubula¹  Peter Lwabi³  James Kayima³  Elias S Sebatta³  Emmanuel Ssekasanvu⁴  Davis Kibirige²  Juliet Nabbaale³ 

[1] Department of Physiology, Makerere University College of Health Sciences, Kampala, Uganda;Department of Medicine, Uganda Martyrs Hospital Lubaga, Kampala, Uganda;Uganda Heart Institute, Mulago Hospital, Kampala, Uganda;Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda

关键词: Uganda;    Africa;    Cross sectional study;    Newly diagnosed hypertensive patients;    Left ventricular mass index;    left ventricular hypertrophy;    Microalbuminuria;   

Others  :  1232457
DOI  :  10.1186/s13104-015-1156-2

 received in 2014-09-24, accepted in 2015-04-30,  发布年份 2015

【 摘 要 】

Background

Microalbuminuria is an early manifestation of kidney damage and independently predicts cardiovascular disease (CVD). Left ventricular hypertrophy (LVH) is also an early marker of cardiac manifestation of target organ damage among hypertensive patients. The prognostic significance of microalbuminuria and its correlation with left ventricular hypertrophy has not been extensively studied in African adult hypertensive populations. This study aimed at determining the prevalence of microalbuminuria, LVH in patients with microalbuminuria and the correlation between microalbuminuria and LVH among newly diagnosed black adult hypertensive patients attending a large outpatient hypertension clinic or admitted on the cardiology ward at Mulago national referral and teaching hospital and Uganda Heart Institute in Kampala, Uganda.

Methods

In this cross-sectional study, 256 newly diagnosed eligible black adult hypertensive patients attending the outpatient hypertension clinic or admitted on the cardiology ward at Mulago national referral and teaching hospital and the Uganda Heart Institute, Kampala Uganda were consecutively recruited over a period of 5 months. Data on socio-demographics, clinical and laboratory findings of the study participants was collected using a pre tested questionnaire. Two spot urine samples were collected to assess for microalbuminuria. Echocardiography (ECHO) was done to assess for the left ventricular mass index using the formula of Teicholz as evidence for early hypertensive heart disease.

Results

The mean age/standard deviation of the study participants was 54.3 ± 6.2 years with a female predominance (162, 63.3 %). The prevalence of microalbuminuria among newly diagnosed hypertensive patients was 39.5 %. The prevalence of LVH among patients with microalbuminuria was found to be 17 %. There was a positive correlation between microalbuminuria and left ventricular hypertrophy among the newly diagnosed adult hypertensive patients at Mulago Hospital (r = 0.185, p = 0.003).

Conclusions

This study demonstrates that microalbuminuria is highly prevalent among newly diagnosed black hypertensive patients and in the presence of LVH. There is also a positive correlation between microalbuminuria and LVH among newly diagnosed hypertensive patients. Since it is a less costly and readily available test, it can be used to predict presence of LVH especially in resource limited settings where ECHO services are not readily available.

【 授权许可】

   
2015 Nabbaale et al.; licensee BioMed Central.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Santulli G: Epidemiology of Cardiovascular Disease in the 21st Century: updated numbers and updated fact. JCvD 2013, 1(1):1-2.
• [2]WHO/Cardiovascular diseases. http://www.who.int/mediacentre/factsheets/fs317/en/ accessed 26 January 2015.
• [3]Hendriks M, Wit F, Roos M, Brewster L, Akande T, de-Beer I, et al.: Hypertension in Sub-Saharan Africa: Cross-Sectional Surveys in Four Rural and Urban Communities. PLoS One 2012., 7Article ID e32638
• [4]Santulli G, Cipolletta E, Soriento D, Del Giudice C, Anastasio A, Monaco S, et al.: CaMK4 Gene Deletion Induces Hypertension. J Am Heart Assoc 2012, 1(4):001081.
• [5]Williams A: The Blood Pressure of Africans. East African Med J 1941, 18:145-52.
• [6]Shaper AG: Blood pressure and body build in a rural community in Uganda. East Afr Med J 1969, 46:228-45.
• [7]Maher D, Waswa L, Baisley K, Karabarinde A, Unwin N, Grosskurth H: Distribution of hyperglycaemia and related cardiovascular disease risk factors in low-income countries: a cross-sectional population-based survey in rural Uganda. Int J Epidemiol 2011, 40:160-71.
• [8]Wamala J, Karyabakabo Z, Ndungutse D, Guwatudde D: Prevalence factors associated with Hypertension in Rukungiri District, Uganda - A Community-Based Study. Afr Health Sci 2009, 9(3):153-60.
• [9]Nuwaha F, Musinguzi G: Pre-hypertension in Uganda: a cross-sectional study. BMC Cardiovasc Disord 2013, 13:101. BioMed Central Full Text
• [10]Kotwani P, Kwarisiima D, Clark T, Kabami J, Geng E, Jain V, et al.: Epidemiology and awareness of hypertension in a rural Ugandan community: a cross-sectional study. BMC Public Health 2013, 13:1151. BioMed Central Full Text
• [11]Abdelhafiz A, Ahmed S, El-Nahas M: Microalbuminuria: Marker or Maker of Cardiovascular Disease. Nephron Exp Nephrol 2011, 119(suppl 1):e6-e10.
• [12]Stehouwer C, Smulders Y: Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms. J Am Soc Nephrol 2006, 17:2106-11.
• [13]Bombelli M, Facchetti R, Carugo S, Madotto F, Arenare F, Quarti-Trevano F, et al.: Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of office blood pressure values. J Hypertens 2009, 27:2458-64.
• [14]Hsieh B: Prognostic value of electrocardiographic criteria for left ventricular hypertrophy. Am Heart J 2005, 150:161-7.
• [15]George T, Ajit M, Abraham G: Beta blockers and left ventricular hypertrophy regression. Indian Heart J 2010, 62(2):139-42.
• [16]Rayner B, Becker P: The prevalence of MA and ECG LVH in hypertensive patients in private practices in South Africa. Cardiovasc J South Afr 2006, 17:245-9.
• [17]Böhm M, Thoenes M, Danchin N, Reil J, Volpe M: Overview of the i-SEARCH Global Study: cardiovascular risk factors and microalbuminuria in hypertensive individuals. High Blood Press Cardiovasc Prev 2008, 15(4):217-24.
• [18]Habbal R, Sekhri A, Volpe M: Prevalence of microalbuminuria in hypertensive patients and its associated cardiovascular risk in clinical cardiology: Moroccan results of the global i-SEAR CH survey - a sub-analysis of a survey with 21 050 patients in 26 countries worldwide. Cardiovasc J Afr 2010, 21:200-5.
• [19]Busari O, Opadijo G, Olarewaju T, Omotoso A, Jimoh A: Electrocardiographic correlates of microalbuminuria in adult Nigerians with essential hypertension. Cardiol J 2010, 17(3):281-7.
• [20]Forlemu A, Menanga A, Ashuntantang G, Kingue S: Urinary Protein Excretion Is Associated with Left Ventricular Hypertrophy in Treatment- Naïve Hypertensive Patients in an African Hospital Setting. Cardiorenal Med 2013, 3:57-62.
• [21]Hitha B, Pappachan J, Pillai H, Sujathan P, Ramakrishna C, Jayaprakash K, et al.: Microalbuminuria in Patients with Essential Hypertension and its Relationship to Target Organ Damage: An Indian Experience. Saudi J Kidney Dis Transpl 2008, 19(3):411-9.
• [22]Pontremoli R, Ravera M, Bezante G, Viazzi F, Nicolella C, Berruti V, et al.: Left ventricular geometry and function in patients with essential hypertension and microalbuminuria. J Hypertens 1999, 17:993-1000.
• [23]Wachtell K, Palmieri V, Olsen M, Bella JN, Aalto T, Dahlöf B, et al.: Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE study. Losartan Intervention for Endpoint Reduction. Am Heart J 2002, 143:319-26.
• [24]Liu J, Robbins D, Palmieri V: Association of albuminuria with systolic and diastolic left ventricular dysfunction in type 2 diabetes: The Strong Heart Study. J Am Coll Cardiol 2003, 41:2022-8.
• [25]Palmieri V, Celentano A, Roman J, de-Simone G, Lewis M, Best L, et al.: Fibrinogen and preclinical echocardiographic target organ damage: the Strong Heart Study. Hypertension 2001, 38:1068-74.